At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VIRX Viracta Therapeutics, Inc.
Market Closed 10-04 16:00:00 EDT
0.2330
+0.0050
+2.19%
盘后0.2330
+0.00000.00%
16:52 EDT
High0.2375
Low0.2285
Vol69.37K
Open0.2285
D1 Closing0.2280
Amplitude3.95%
Mkt Cap9.18M
Tradable Cap5.77M
Total Shares39.42M
T/O16.13K
T/O Rate0.28%
Tradable Shares24.78M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Leerink Partners Downgrades Viracta Therapeutics to Market Perform From Outperform, Adjusts PT to $3 From $5
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.